• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer's disease. Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials. PMID: 28676010 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - June 30, 2017 Category: Drugs & Pharmacology Authors: Brown BM, Pressley B, Wulff H Tags: Curr Neuropharmacol Source Type: research